Atlas Trials

A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SARS-CoV-2 Infection

Clinical trial NCT05472090 · COMPLETED

Trial details

NCT number
NCT05472090
Sponsor
Tonix Pharmaceuticals, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Post-Acute Sequelae of SARS-CoV-2 (PASC) InfectionCOVID-19Long COVIDLong Haul COVID
Start date
2022-08-18
Primary completion
2023-07-12
Enrollment
63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.